Overview

Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The study aims to evaluate MN-166 (ibudilast) in patients with COVID-19 who are at risk of developing acute respiratory distress syndrome. Subjects will be screened, randomly assigned to MN-166 or placebo groups, receive study drug on Days 1-7, and followed up on Day 14 and Day 28.

Phase:

Phase 2

Details

Lead Sponsor:

MediciNova

Treatments:

Ibudilast